Study finds among outpatients with mild to moderate COVID-19, treatment with fluvoxamine does not reduce duration of symptoms Post author: Post published:November 22, 2023 Post category:uncategorized Researchers investigate the effects of high-dose fluvoxamine among patients with mild-to-moderate COVID-19. You Might Also Like Yale chemists synthesize complex anticancer molecules from marine invertebrates February 22, 2024 Kidney donors’ mortality risk drops significantly over the past decade August 28, 2024 SHEA calls for continued U.S. partnership with the World Health Organization January 21, 2025